ISIS Pharmaceuticals (ISIS) is a dynamic biotechnology company focused on the development of antisense oligonucleotides (ASOs) as drugs. Its chief antisense oligonucleotide (ASO) is Kynamro (mipomersen), which is used to lower cholesterol. After reviewing available long-term data on Kynamro, I will show that Kynamro has qualities that make for a very poor drug because:
1. It is poorly tolerated.
2. It is immunogenic.
3. The immune response is associated with increased adverse events.
4. Long-term use leads to increased adverse events.
As acknowledged by ISIS CEO Stanley Crooke in a recent review, Kynamro (mipomersen) is a representative molecule of ISIS second generation antisense oligonucleotides (ASOs). He states:
Mipomersen is representative of second generation ASOs. As all ...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|